Due to its aggressive behavior the identification of the inactivation and loss of BRG1 (SMARCA4) has become of interest for lung cancer management as recent preclinical studies have discussed therapeutic vulnerabilities that may overcome the inherently aggressive biology of SMARCA4 - deficient NSCLCs11–13. This evidence concerns the gene SMARCA4 and lung cancer.